Clinical trials
Neoplasms clinical trials
Below are recruiting neoplasms clinical trials, each written for real people, not researchers. We’re tracking 1,642 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04641247RecruitingPhase 2
Long-term niraparib follow-up for people already benefiting
This study looks at continuing niraparib for a longer time in people who already finished an earlier niraparib trial and are still benefiting. It may help understand how safe and useful long-term treatment is for you.
Tucson, ArizonaAges 18 years+ - NCT04557969Recruiting
Surgery and tumor testing in gastrointestinal stromal tumors (GIST)
This study looks at how surgery for gastrointestinal stromal tumors (GIST) works, and collects tumor samples to study them under the microscope and by DNA testing. Your results may help researchers better predict tumor behavior and guide future treatment.
Bethesda, MarylandAges 6 years+ - NCT04585958RecruitingPhase 1
Combination treatment for HER2-positive cancers and resistant ovarian cancer
This trial tests a new combination of two drugs, DS-8201a and olaparib, for people with cancers that have a protein called HER2, and for those with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if this combination can shrink or control the cancer.
Phoenix, ArizonaAges 18 years+ - NCT04534127Recruiting
DaRT radiation device for skin and mouth or superficial tumors
This trial tests a targeted radiation device (DaRT seeds) to treat certain cancers on the skin, in the mouth, or in superficial soft tissue. It may help when standard treatment (like surgery or regular radiation/chemo) hasn’t worked, isn’t safe, or isn’t wanted.
JerusalemAges 18 years+ - NCT04551378Recruiting
Study of how COVID affected young people with cancer
This study looks at how the COVID-19 pandemic affected the experiences of teenagers and young adults with cancer, including people who finished treatment. It may help improve support for cancer patients and survivors during public health crises.
Houston, TexasAges 18–39 - NCT04494945Recruiting
Help for people with inherited cancer risk genes
This study helps identify people who may have an inherited cancer risk and checks how best to support them. Depending on the group, you may only fill out surveys, or you may also create an app account and possibly provide a DNA sample.
Portland, OregonAges 18 years+ - NCT04515810Recruiting
Mobile app coaching for planning care after serious cancer
This study tests a mobile health app (PACT) to help people with advanced cancer talk and plan for future care. It may help you and a loved one stay engaged in advance care planning (planning what care you want and who should speak for you).
Manhasset, New YorkAges 18 years+ - NCT04266093Enrolling by invitation
Gene therapy follow-up for adults previously treated at NCI
This study is a follow-up check for people who were previously enrolled in certain NCI gene therapy treatment studies. It helps the research team monitor long-term effects and outcomes after treatment.
Bethesda, MarylandAges 18–120 - NCT04278118Recruiting
Proton radiation study for non-cancer brain tumor types
This trial tests a radiation plan that gives treatment in fewer, larger “fractions” using proton beams (or sometimes photon beams) for certain non-cancer brain tumor types. It aims to see how well this approach works while keeping side effects manageable.
Atlanta, GeorgiaAges 18 years+ - NCT04265430RecruitingPhase 4
MRI scans to predict normal-tissue side effects after treatment
This trial uses repeated MRI scans to better predict which patients may develop painful jaw and mouth tissue problems after radiation and/or certain bone or blood-vessel medicines. It may help clinicians spot problems earlier and tailor follow-up care.
Houston, TexasAges 18 years+ - NCT04216524RecruitingPhase 2
Venetoclax plus chemotherapy for blastic dendritic cell cancer
This Phase 2 trial tests venetoclax combined with chemotherapy to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN). It may help shrink BPDCN and control the disease, whether you’re newly diagnosed or the cancer has come back.
Houston, TexasAges 18 years+ - NCT04242095Recruiting
Immunotherapy side effects research study
This study collects blood, stool, and tissue samples from people who have had side effects from immunotherapy (a type of cancer treatment that helps your immune system fight cancer). It aims to learn more about these side effects, so doctors can better manage them in the future.
Anchorage, AlaskaAges Any age - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT03816345RecruitingPhase 1
Nivolumab for advanced cancer with autoimmune disease
This trial tests whether the immunotherapy drug nivolumab can safely treat advanced cancer in people who also have an autoimmune disease like rheumatoid arthritis, lupus, or multiple sclerosis. It aims to find out if the drug may help control cancer while managing their autoimmune condition.
Birmingham, AlabamaAges 18 years+ - NCT03750227RecruitingPhase 3
Radiation before or after brain tumor surgery
This study compares giving focused, high-precision radiation before or after surgery for brain metastases. It aims to see which timing works best to control tumors and improve outcomes.
Scottsdale, ArizonaAges 18 years+ - NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT03573791Recruiting
Testing markers to predict chemo-radiation response in rectal cancer
This trial studies lab “biomarkers” (measurable cancer features) to predict whether rectal cancer will resist chemo-radiation before surgery. The goal is to help doctors better choose treatments and avoid ineffective therapy.
Wuhan, HubeiAges 18–75 - NCT03429036Recruiting
Collecting head and neck tissue samples for research
This study collects tissue and fluid samples from people with head and neck disorders to help researchers learn more about these conditions. By donating leftover samples from your regular medical care, you can help advance research without extra procedures.
Washington D.C., District of ColumbiaAges 3–120 - NCT03422302Recruiting
CPAP or breath-holding to reduce lung tumor motion
This study looks at whether using a CPAP breathing device or deep breath-holding can keep lung tumors from moving during targeted radiation. The goal is to improve safety and accuracy of stereotactic body radiation for lung cancer.
Houston, TexasAges 18 years+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT03270059RecruitingPhase 2
MRI with special contrast to study brain and other CNS problems
This trial tests whether two special MRI contrast medicines—gadolinium and ferumoxytol—can better diagnose problems in the brain or central nervous system. It may help doctors identify what’s causing symptoms or abnormal brain findings.
Portland, OregonAges 10 years+ - NCT03221335Recruiting
Ultrasound-guided heat treatment for certain abdominal tumors
This trial studies using a camera-guided, ultrasound-guided heat procedure to treat solid tumors in the stomach, liver, kidney, or adrenal glands. It may help people who cannot safely have surgery, or who prefer a non-surgical option.
Hong KongAges 18 years+ - NCT03207854Recruiting
Donate blood and immune samples for cancer, blood, or healthy volunteers study
This study collects blood and immune-related samples from people with cancer, certain immune-related blood conditions, or healthy volunteers. It helps researchers understand immune changes and may support future diagnosis or treatments.
Los Angeles, CaliforniaAges 19 years+
Hear when a new Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for neoplasms?
- Yes. Clin2 currently lists 1,642 recruiting neoplasms studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a neoplasms trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a neoplasms trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.